Social media

As global pressures reshape the pharmaceutical and biotech landscape, sponsors are re-evaluating their outsourcing strategies. In this article, Maria DiPietro shares insights from ICON’s recent survey of industry stake...

ICON is advancing site and patient engagement through innovation. At the SCRS Global Site Solutions Summit, discover how Accellacare and FIRECREST are delivering integrated site support and digital enablement to drive tr...

ICON is advancing site and patient engagement through innovation. At the SCRS Global Site Solutions Summit, discover how Accellacare and FIRECREST are delivering integrated site support and digital enablement to drive tr...

While cardiovascular outcomes trials are often required by regulators, and critical to demonstrating clinical value, they can be costly and complex to conduct. To realise their full benefit, sponsors must be strategic ...

Submitting clinical data to both the FDA and PMDA does not need to be a duplicated effort. With the right approach, regulatory teams can streamline their processes and improve the quality of their submissions. Our new wh...

Submitting clinical data to both the FDA and PMDA does not need to be a duplicated effort. With the right approach, regulatory teams can streamline their processes and improve the quality of their submissions. Our new wh...

ICON will be launching our new multiplex immunofluorescence services at Biomarkers & Precision Medicine. Come along to booth \#51 to find out how our comprehensive services—from panel design to AI-powered image analysis—...

A LinkedIn profile is more than a professional summary, it's a way to demonstrate your expertise, connect with peers and share your career journey. By investing time in building and maintaining your profile, you make it ...

Clinical development processes for pediatric trials differ from adult trials. Register for our webinar to learn about regulatory strategies and tools in developing pediatric clinic trials and an interactive tool which he...

Identifying the differences between the clinical development processes for pediatric trials and adult trials can be difficult, especially when resources are constrained. Join ICON’s Heather Peterson and Jo Dewhurst for a...

Are you attending #WorldCDx? Stop by booth \#13 and meet with our VP Scientific Affairs Sean Downing, PhD MBA and biomarker expert Jin Li who will be happy to discuss how ICON’s biomarker expertise drives smarter trials,...

We’re celebrating a major milestone. ICON has been named one of TIME and Statista’s World’s Best Companies of 2025 — for the third year in a row. This recognition is all about our people, our purpose and our passion. Tha...